Skip to content

Spyre Therapeutics

US · SYRE #1646 by market cap Listed 1970
93.47 -4.16 -4.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Quant vs Street three independent views, side by side

StockVane factor grade
B+
Momentum strategy signal
Hold
Analyst consensus
Buy

Mostly aligned, one view stands apart.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

Analyst consensus 13 analysts

Buy
Avg price target 123.38 +32.0%
Price target rangecurrent 93.47
Low115.00
Avg123.38
High135.00
Buy 100% Hold 0% Sell 0%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-11-12 J.P. Morgan -- Buy 116.00
2026-11-05 Wells Fargo -- Buy 115.00
2026-11-04 Wells Fargo -- Buy 115.00
2026-11-04 JonesTrading -- Buy 130.00
2026-11-04 BTIG -- Buy 121.00
2026-11-04 Wedbush -- Buy 120.00
2026-11-04 Stifel -- Buy 131.00
2026-11-03 Guggenheim -- Buy 135.00
2026-10-21 Citi -- Buy 119.00
2026-10-20 Citi -- Buy 119.00
2026-10-19 BTIG -- Buy 121.00
2026-10-19 Wedbush -- Buy 123.00
2026-10-12 UBS -- Buy 120.00
2026-10-11 UBS -- Buy 120.00
2026-10-02 Wells Fargo -- Buy 115.00
2026-10-01 JonesTrading -- Buy 130.00
2026-10-01 J.P. Morgan -- Buy 110.00
2026-09-27 JonesTrading -- Buy 121.00
2026-09-10 Leerink Partners -- Buy 128.00
2026-09-09 Wedbush -- Buy 123.00
2026-09-09 Jefferies -- Buy 126.00
2026-09-09 Leerink Partners -- Buy 128.00
2026-09-08 LifeSci Capital -- Buy 116.00
2026-08-29 LifeSci Capital -- Buy 116.00
2026-08-26 LifeSci Capital -- Buy 116.00

Price target trend monthly average, last 3 years

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Spyre Therapeutics discussion 0 comments

Add a comment